Inflammatory bowel disease (IBD) is a set of complex and devastating diseases, for which there is no satisfactory treatment. The two major forms of IBD are Ulcerative Colitis and Crohn’s disease and the estimated cost of these diseases is 2.7 billion dollars annually in Australia. The incidence of the disease in Australia has been rising, corresponding with the increasing level of incidence in other first world countries that have genetic and lifestyle similarities. Recent studies have shown a range of small peptides may have potential in the design of novel drug leads for the treatment of IBD. However, these small peptides are likely to be unstable and thus, non-viable drug leads. Improving the stability of peptides through grafting them into a stable cyclic peptide scaffold may enhance their therapeutic potential. Using this approach we have designed a novel cyclic peptide that is able to reduce the symptoms in a TNBS induced colitis mouse model. Further studies are now required to understand the mechanism of action of this peptide and explore the potencies of other analogues.